Leadless pacemaker technology is expanding its ability to treat more patients with dual-chamber pacing.

The study, published in the American Journal of Cardiology, included data from more than 900 TAVR patients. Overall morality was 22.7% among patients with AFib and 14.4% among patients without AFib.

The FDA would approve trials on a case-by-case basis, according to an anonymous source close to the situation. 

Researchers compared the new-look drug coated balloon with an uncoated balloon, publishing their findings in JACC: Cardiovascular Interventions.

The additional costs associated with AFib ablation appear to be justified, researchers wrote.

A universal vaccine would offer broader and longer-lasting protection against seasonal flu viruses and new flu viruses.

The FDA is warning patients and referrers about an imaging business near the nation’s capital that has fumbled away its mammography accreditation.